BUZZ - Vaxcyte shares soar following successful late-stage clinical trial for pneumococcal vaccine
路透社2026/10/05 10:26October 5 – Vaxcyte (PCVX.O) shares surged 26% pre-market to $71.17. Vaxcyte announced that its 31-valent pneumococcal vaccine VAX-31 met all primary endpoints in a late-stage clinical trial, and generated immune responses comparable to or stronger than Pfizer’s Prevnar 20 and Merck’s Capvaxive. The safety and tolerability of the vaccine were similar to existing vaccines. Vaxcyte expects results from two additional late-stage clinical trials in the first half of 2027, and plans to submit a marketing application to the FDA in the first half of 2028. As of the previous trading session’s close, the stock had risen 22.4% year-to-date.
October 5 - ** Vaxcyte (PCVX.O) shares surged 26% in pre-market trading to $71.17
** Vaxcyte stated that its 31-valent pneumonia vaccine VAX-31 met all primary endpoints in a late-stage clinical trial (link) and generated an immune response comparable to or stronger than that of Pfizer's PFE.N Prevnar 20 and Merck's MRK.N Capvaxive
** The safety and tolerability of the vaccine were comparable to existing vaccines
** Vaxcyte expects to obtain results from two additional late-stage clinical trials in the first half of 2027 and plans to submit a marketing application to the FDA in the first half of 2028
** As of the close of the previous trading day, the stock had risen 22.4% year-to-date
(To facilitate non-English speakers, Reuters provides automated translations of its reports into several other languages. Automated translation may be inaccurate or may fail to capture the intended meaning, and Reuters makes no guarantee regarding the accuracy of the translated text. Automated translation is provided solely for the convenience of readers. Reuters accepts no liability for any damages or losses arising from the use of this automated translation function.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Samsung Electronics delivers its strongest quarterly report ever; can HBM4e restart AI memory trading?
Samsung Electronics is about to face a critical test. The company will release its preliminary results on Thursday, and it is expected to record its largest-ever quarterly operating profit. However, the real test is not the scale of profits, but whether it can convince investors that the demand for memory chips is sustainable and that high product prices can be secured through long-term contracts.
BUZZ - Australian uranium mining stocks surge after Google reaches power deal with Constellation Energy
October 7 - Shares of Australian uranium mining companies surged after Google (GOOGL.O) signed a power agreement with Constellation Energy (CEG.O), the largest nuclear power plant operator in the United States (link). Google (GOOGL) and Constellation Energy (CEG) have entered into a multi-year deal under which Google will purchase 3,590 megawatts of electricity from Constellation; according to both parties, the additional nuclear-generated electricity accounts for roughly a quarter of total supplied power. Uranium is primarily used as fuel for nuclear power plants to generate low-carbon electricity. Boss Energy (BOE.AX) shares rose 9%, reaching their highest level since September 29, while Paladin Energy (PDN.AX) shares climbed over 6%. Deep Yellow (DYL.AX) shares rose nearly 10%, marking their largest intraday gain since September 3. Within the broadly flat ASX200 benchmark index (.AXJO), DYL and PDN ranked among the top gainers. (For the convenience of non-English speakers, Reuters has automatically translated its reports into several other languages. Since automated translations may contain errors or lack the necessary context, Reuters does not guarantee their accuracy and provides them solely for reader convenience. Reuters accepts no responsibility for any damage or loss arising from the use of the automated translation function.)
12.41 million dollars in fee revenue, Pump.fun transferred to an exchange 9 hours ago
JPMorgan: U.S. deep non-performing loans rise to pandemic-era highs, tech industry hardest hit
JPMorgan strategists wrote on Tuesday that the tail of the leveraged loan market's deep distress has risen to its highest level since the onset of the pandemic, with technology being the single most pressured sector.
Crypto prices
More
